CL2023000477A1 - Proteínas de unión restringidas activadas de forma condicional - Google Patents

Proteínas de unión restringidas activadas de forma condicional

Info

Publication number
CL2023000477A1
CL2023000477A1 CL2023000477A CL2023000477A CL2023000477A1 CL 2023000477 A1 CL2023000477 A1 CL 2023000477A1 CL 2023000477 A CL2023000477 A CL 2023000477A CL 2023000477 A CL2023000477 A CL 2023000477A CL 2023000477 A1 CL2023000477 A1 CL 2023000477A1
Authority
CL
Chile
Prior art keywords
binding proteins
conditionally activated
restricted binding
activated restricted
conditionally
Prior art date
Application number
CL2023000477A
Other languages
English (en)
Spanish (es)
Inventor
B Dubridge Robert
Timothy Chen Tseng-Hui
A Culp Patricia
Michael May Chad
Dettling Danielle
Degenhardt Jeremiah
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2023000477A1 publication Critical patent/CL2023000477A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2023000477A 2020-08-17 2023-02-16 Proteínas de unión restringidas activadas de forma condicional CL2023000477A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063066565P 2020-08-17 2020-08-17

Publications (1)

Publication Number Publication Date
CL2023000477A1 true CL2023000477A1 (es) 2023-11-10

Family

ID=77655705

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000477A CL2023000477A1 (es) 2020-08-17 2023-02-16 Proteínas de unión restringidas activadas de forma condicional

Country Status (16)

Country Link
US (1) US20240026011A1 (enExample)
EP (1) EP4196503A2 (enExample)
JP (1) JP2023538366A (enExample)
KR (1) KR20230048146A (enExample)
CN (1) CN116419925A (enExample)
AR (1) AR123266A1 (enExample)
AU (1) AU2021329290A1 (enExample)
CA (1) CA3191431A1 (enExample)
CL (1) CL2023000477A1 (enExample)
CO (1) CO2023002164A2 (enExample)
EC (1) ECSP23018458A (enExample)
IL (1) IL300598A (enExample)
MX (1) MX2023002002A (enExample)
PE (1) PE20230856A1 (enExample)
TW (1) TW202214707A (enExample)
WO (1) WO2022040128A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
MX2020002667A (es) 2017-09-08 2020-08-03 Maverick Therapeutics Inc Proteinas de unión condicionalmente activadas restringidas.
TW202342521A (zh) * 2022-02-23 2023-11-01 日商武田藥品工業股份有限公司 條件性雙特異性結合蛋白
WO2024040220A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding fusion proteins
WO2024040228A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding proteins
WO2024147897A2 (en) * 2023-01-05 2024-07-11 Harpoon Therapeutics, Inc. Trop2 targeting trispecific protein for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
TW201808990A (zh) 2016-03-08 2018-03-16 馬弗瑞克療法公司 可誘導性結合蛋白和使用方法
MX2020002667A (es) 2017-09-08 2020-08-03 Maverick Therapeutics Inc Proteinas de unión condicionalmente activadas restringidas.
CN120484127A (zh) 2019-03-05 2025-08-15 武田药品工业有限公司 受约束的条件性活化的结合蛋白

Also Published As

Publication number Publication date
JP2023538366A (ja) 2023-09-07
WO2022040128A2 (en) 2022-02-24
MX2023002002A (es) 2023-07-06
CA3191431A1 (en) 2022-02-24
TW202214707A (zh) 2022-04-16
PE20230856A1 (es) 2023-05-29
US20240026011A1 (en) 2024-01-25
ECSP23018458A (es) 2023-04-28
WO2022040128A3 (en) 2022-04-07
EP4196503A2 (en) 2023-06-21
KR20230048146A (ko) 2023-04-10
AU2021329290A1 (en) 2023-04-13
CN116419925A (zh) 2023-07-11
IL300598A (en) 2023-04-01
AR123266A1 (es) 2022-11-16
CO2023002164A2 (es) 2023-03-07

Similar Documents

Publication Publication Date Title
CL2023000477A1 (es) Proteínas de unión restringidas activadas de forma condicional
CL2023000972A1 (es) Inhibidores de ras
MX2020009568A (es) Anticuerpos que se unen a cd39 y sus usos.
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
CL2025000457A1 (es) Inhibidores de ras
CL2023000974A1 (es) Inhibidores de ras
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
CA3216726C (en) Il-15-based fusions to il-12 and il-18
IL282362A (en) Intein proteins and uses thereof
DK3849614T3 (da) Interleukin-2-polypeptidkonjugater og anvendelser deraf
EP3898654A4 (en) FIBROBLAST ACTIVATION PROTEIN INHIBITORS
DOP2018000245A (es) Proteinas de fusion gdf15 y usos de estas
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
EP3544628A4 (en) 4-1BB BINDING PROTEINS AND THEIR USES
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
PL3576788T3 (pl) Kompozycja farmaceutyczna o niskim ph zawierająca konstrukty przeciwciał angażujących komórki t
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EP3976630A4 (en) Actrii-binding proteins and uses thereof
IL290910A (en) Modified tff2 polypeptides containing compositions and methods of use thereof
DOP2017000246A (es) Polipéptidos dirigidos a la fusión de vih
CL2022000894A1 (es) Moduladores atf6 y sus usos.